Anbio BiotechnologyNNNN -2.96%24 EBIT per Share is $0.13 as of Dec. 2025. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 67.98% on this metric.
Anbio Biotechnology's EBIT per Share for the
six
months ended in Dec. 2025 was $0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.13.
During the past 12 months, the average EBIT per Share Growth Rate of Anbio Biotechnology was 193.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 23.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Anbio Biotechnology's EBIT per Share or its related term are showing as below:
NNNN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 21.6 Med: 22.3 Max: 23
Current: 23
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Anbio Biotechnology was 23.00% per year. The lowest was 21.60% per year. And the median was 22.30% per year.
NNNN's 3-Year EBIT Growth Rate is ranked better than 67.98% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.4
vs NNNN: 23.00
Anbio Biotechnology (NAS:NNNN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Anbio Biotechnology EBIT per Share Related Terms
Anbio Biotechnology EBIT per Share Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a EBIT per Share of $0.13 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Anbio Biotechnology and its competitors. According to the industry distribution chart, Anbio Biotechnology ranks #220 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 32%.
Is Anbio Biotechnology's EBIT per Share too high?
Anbio Biotechnology's current EBIT per Share is $0.13. The Medical Devices & Instruments industry median EBIT per Share is 9.40. Anbio Biotechnology's value of $0.13 is 98.6% below this industry median. Based on the distribution chart, Anbio Biotechnology ranks #220 out of 687 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EBIT per Share compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #220 out of 687 companies for EBIT per Share. This puts Anbio Biotechnology in the upper half of its industry. The industry median EBIT per Share is 9.40. Anbio Biotechnology's value of $0.13 is 98.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.40, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current EBIT per Share of $0.13 is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current EBIT per Share is $0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EBIT per Share of $0.13. The current EBIT per Share is $0.13 and 98.6% below the Medical Devices & Instruments industry median of 9.40. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EBIT per Share is $0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
